在暴露于CDK4/6抑制剂后,富勒斯特兰特单一疗法的有效性:这是一个可行的选择吗?
Nanae Ogata1,2, Brian G Barnett3, Nicholas J H Sharp3
1Translational and Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI 96813, USA.
Cancers
|March 13, 2025
概括
在晚期乳腺癌中使用CDK4/6抑制剂治疗后,富尔韦斯坦单疗是一种常见的选择. 然而,它的有效性是有限的,这表明临床试验对于新的选择至关重要.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 对于HR+,HER2-高级乳腺癌的第一线治疗,现在倾向于CDK4/6抑制剂加上内分泌治疗.
- 在CDK4/6抑制剂进展后,最佳后续疗法,特别是对于没有可操作突变的瘤,仍然是一个临床挑战.
研究的目的:
- 对复发性或复发性乳腺癌的CDK4/6后抑制剂设置中富尔韦斯特兰特单一治疗的治疗潜力进行审查.
- 分析临床试验数据关于富尔韦斯特兰特的疗效和影响因素在这个特定的患者群体.
主要方法:
- 在PubMed和ClinicalTrials.gov (2017年11月至2024年) 的系统文献搜索.
- 纳入了10项研究,重点是对1038名先前暴露于CDK4/6抑制剂的患者的富勒韦斯特兰单疗法.
- 将试验分类为单疗法,组合疗法和CDK4/6抑制剂再挑战组.
主要成果:
- 富尔韦斯特兰特单独治疗的无进展生存时间中位数为3.18个月 (范围为1.9-5.3个月).
- 富尔韦斯特兰特单一治疗的有效性受先前治疗,先前治疗的持续时间和特定基因突变的影响.
- 这些研究包括单疗法试验 (EMERALD,SERENA-2,AMEERA-3,ELAINE-1),组合试验 (CAPItello-291,VERONICA) 和重新挑战试验 (后MONARCH,PACE,PALMIRA,MAINTAIN).
结论:
- 在CDK4/6抑制剂进展后,富尔韦斯特兰特单一疗法在第二次或随后的治疗线上显示出有限的疗效.
- 对于在这种环境中寻求新型治疗选择的患者,建议参加临床试验.
关键词:
抗体与药物结合剂 (ADCs) 是一种抗体与药物结合剂.乳腺癌 乳腺癌 乳腺癌环林依赖性激酶4和6抑制剂 (CDK4/6抑制剂)富尔维斯特兰特 (Fulvestrant) 是一个充满活力的项目.蛋白质激酶抑制剂蛋白质激酶抑制剂核糖体蛋白 S6 激酶 2 (RSK2) 的作用.更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
8.2K
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
